Head and neck cancers are the seventh-leading cancer by incidence worldwide.^[@bibr1-2473974X20942202]^ They are mostly composed of head and neck squamous cell carcinoma (HNSCC), which develops in the mucous membrane of several locations, such as the mouth, throat, larynx, nose, and sinuses. Despite recent therapeutic advances, the 5-year overall survival is still at \~50%.^[@bibr2-2473974X20942202]^ In 2012, the worldwide burden of HNSCC was \~600,000, and the recorded death was \~300,000.^[@bibr1-2473974X20942202],[@bibr2-2473974X20942202]^ This incidence and mortality of HNSCC are higher in countries with emerging health care systems, due to ineffective prevention strategy, late screening, and suboptimal diagnostic and therapeutic tools.^[@bibr3-2473974X20942202]^ According to the World Bank, 71% (41/98) of low- and middle-income countries are in Africa (<https://data.worldbank.org/income-level/low-and-middle-income>). There have been reports of dissimilarities in the genetic etiology of cancer based on ethnic differences in mutations.^[@bibr4-2473974X20942202]^ This is due mainly to locus heterogeneity among ethnic groups, immune-mediated response, and corroboration of Eurasian population reports.^[@bibr4-2473974X20942202],[@bibr5-2473974X20942202]^ These Eurasian populations contribute a subset to the human genome and do not fully characterize susceptible variants, particularly those of Africans, who exhibit higher genetic diversity and demonstrate less gene linkage disequilibrium.^[@bibr5-2473974X20942202]^ Several genetic disease studies have provided ample evidence of overlap in disease-causal alleles between ancestry groups and diverse communities.^[@bibr6-2473974X20942202],[@bibr7-2473974X20942202]^ This overlap of the underlying causal allele at several loci across ancestry improves the power to detect disease-susceptible loci and improve causal variant mapping.^[@bibr8-2473974X20942202]^ Our group has published the most comprehensive catalog of susceptible genes and polymorphisms in African population--based cancers with limited reports on HNSCC candidate alleles.^[@bibr9-2473974X20942202]^ While there are several reports on HNSCC candidate genes,^[@bibr10-2473974X20942202],[@bibr11-2473974X20942202]^ there remains no catalog of candidate genes for African population--based HNSCC. Reviewing genetic polymorphisms in HNSCC in African populations will appraise the current evidence and gene distinction from the known HNSCC candidate genes.

Etiology of HNSCC {#section6-2473974X20942202}
=================

Tobacco use, alcohol consumption, and human papillomavirus (HPV) are identified as the main causative factors of initiation and progression of HNSCC. While the correlation of E6/E7 mRNA gene expression to the genotoxic activity of HPV 16/18 in oropharyngeal cancer has been established,^[@bibr12-2473974X20942202],[@bibr13-2473974X20942202]^ there is yet to be an understanding of the molecular correlation between oral cancer and nicotine subunits/tobacco alkaloids that give rise to tobacco-specific N-nitrosamines.^[@bibr14-2473974X20942202],[@bibr15-2473974X20942202]^ Except for high-risk HPV status, quite a number of these molecular risk factors have limited clinical use.

Genetics of HNSCC {#section7-2473974X20942202}
=================

The major cellular function often altered during carcinogenesis is the cell cycle regulation. Cell cycle--regulating genes targeted in HNSCC by carcinogens or HPV oncogenes are mainly those encoding p53 proteins and retinoblastoma pathways.^[@bibr13-2473974X20942202]^ Several studies have investigated the genomic landscape of HNSCC with high-throughput methods and have reported significant single-nucleotide polymorphisms and copy number variations in candidate genes as well as a distinct genetic landscape associated with HPV status.^[@bibr10-2473974X20942202],[@bibr11-2473974X20942202],[@bibr16-2473974X20942202]^ These genes comprise *TP53* (40%-60%), *CDKN2A* (12%-16%), *NOTCH1* (10%-12%), *PIK3CA* (8%), *FAT1* (5%-8%), *HRAS* (5%-8%), *CASP8* (5%-8%), and *PTEN* (3%-7%).^[@bibr10-2473974X20942202],[@bibr16-2473974X20942202]^

This study aimed to catalog the current evidence of the knowledge and genetic data (cohort, cross-sectional, and case-control studies) on HNSCC among African populations, as well as appraise any distinction between known candidate genes and research gaps for future studies.

Materials and Methods {#section8-2473974X20942202}
=====================

Our search methodology was modeled after the Cochrane systematic review protocol. MeSH terms and keywords comprising and related to cancer, HNSCC and subtypes, genetic polymorphism, single-nucleotide polymorphisms, Africa, and African regions and countries were used for the initial search (see [**Table 1**](#table1-2473974X20942202){ref-type="table"}). Publications were selected that interrogated susceptible gene polymorphisms to African-based populations with cancer, comprising North Africans and sub-Saharan Africans, including black South Africans. Those whose combined ancestral origins were not African were excluded (eg, white Africans, African Americans, and African Europeans). Publications were selected with the search tools PubMed (1950-2019), Ovid Medline (1946-2019), and Web of Science (1900-2019). References from these selected publications were searched and appropriately included. The English-language title, abstract, and full text of selected publications were read to identify publications suitable for this review. Genetic studies considered were genetic (candidate gene) association studies and sequencing studies for germline and somatic mutations. As such, purely clinical or pathologic articles were excluded. A modified Quality Assessment Tool--Strengthening the Reporting of Genetic Association (QAT-STREGA) was used to assess the selected articles for study quality.^[@bibr17-2473974X20942202]^ In summary, this QAT-STREGA tool assessed the presence of the following: power calculation, case population characteristics, cancer diagnosis, case and control screening, measure of association with odds ratio, genotyping error, Hardy-Weinberg equilibrium, and rs identification number (per the National Center for Biotechnology Information's variation resource single-nucleotide polymorphism database). The QAT-STREGA score evaluated 9 items, and each had a score of 0 or 1, which can add to a maximum score of 9; a score **≥**5 was deemed an acceptable quality. Data extraction was undertaken with a form that detailed biodata, case and control characterization, genotyping method, and statistical analysis method. Identified genes and polymorphisms from this study were compared with known HNSCC candidate genes and any distinctions were interrogated using The Cancer Genome Atlas--Head and Neck Squamous Cell Cancer (TCGA-HNSC) project database (<http://cancergenome.nih.gov/abouttcga>).

###### 

Search Strategy to Identify Publications on African Head and Neck Squamous Cell Carcinoma.

![](10.1177_2473974X20942202-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  •Search cancer, carcinoma or neoplasm (MeSH)\
  •Search Africa (MeSH)\
  •Search polymorphism or mutation or variants (MeSH)\
  •Search Algeria or Angola or Benin or Botswana or Burkina Faso or Burundi or Cameroon or Cape Verde or Central African Republic or Chad or Comoros or Democratic Republic of Congo or (DRC) or Djibouti or Equatorial Guinea or Egypt or Eritrea or Ethiopia or Gabon or Gambia or Ghana or Guinea or Guinea-Bissau or Ivory Coast or (Côte d'Ivoire) or Kenya or Lesotho or Liberia or Libya or Madagascar or Malawi or Mali or Mauritania or Mauritius or Morocco or Mozambique or Namibia or Niger or Nigeria or Republic of Congo or Rwanda or Sao Tome & Principe or Senegal or Seychelles or "Sierra Leone" or Somalia or "South Africa" or Sudan or Swaziland or Tanzania or Togo or Tunisia or Uganda or Zaire or Zambia or Zimbabwe or "Central Africa" or "West Africa" or "East Africa" or "Southern Africa" or "South Africa"*Field: Title/Abstract*

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The research and ethics review board of the Lagos State University College of Medicine required no ethics approval for this study.

Results {#section9-2473974X20942202}
=======

The study search protocol identified 27 publications from PubMed (n = 16), Ovid Medline (n = 8), and Web of Science (n = 3; see [**Figure 1**](#fig1-2473974X20942202){ref-type="fig"}). Based on the search of the titles and review of abstracts, 21 publications were removed for not being related to HNSCC or genetic polymorphisms or variants. The remaining 6 publications had their full text reviewed and were adjudged to have met the inclusion criteria. One publication from the references was added to make of total of 7 eligible publications. Two HNSCC types were studied in these selected articles: nasopharyngeal and laryngeal carcinomas.

![Search strategy flowchart.](10.1177_2473974X20942202-fig1){#fig1-2473974X20942202}

A total of 6 genetic studies on nasopharyngeal cancer and 1 study on nasopharyngeal and laryngeal cancers were undertaken in 3 of 54 (6%) African countries: Tunisia, Algeria, and Morocco.^[@bibr18-2473974X20942202][@bibr19-2473974X20942202][@bibr20-2473974X20942202][@bibr21-2473974X20942202][@bibr22-2473974X20942202][@bibr23-2473974X20942202]-[@bibr24-2473974X20942202]^ All studies were case-control studies and published between 2007 and 2019 (see [**Tables 2**](#table2-2473974X20942202){ref-type="table"} and [**3**](#table2-2473974X20942202){ref-type="table"}). Sample sizes ranged from 137 to 392 (median, 180) for cases and 168 to 365 (median, 261) for controls. Cancer diagnosis for all cases was by histology. Tissues for DNA extraction were cancer tissue for cases and matching peripheral blood for controls. All studies screened for variants with polymerase chain reaction--based techniques. Thirteen polymorphisms from 10 genes were screened: *NOS3, CYP1A1, CYP2D6, NAT1, NAT2, NQO1, IL-10, IL-12, IL-8*, and *COX2*. All studies reported risk ratios; 6 of 7 studies tested the Hardy-Weinberg equilibrium; and 4 of 7 studies reported the rs numbers per the National Center for Biotechnology Information. All studies had a QAT-STREGA score \>5, and 10 of 13 variants showed a statistically significant association to target gene polymorphism. Additional details of these studies are shown in [**Table 2**](#table2-2473974X20942202){ref-type="table"} and [**Table 3**](#table3-2473974X20942202){ref-type="table"}.

###### 

Quality Assessment of Genetic Studies.

![](10.1177_2473974X20942202-table2)

                                                                                                    Power calculation   NPC diagnosis description   Screening of NPC controls   Population characteristics   NCBI rs Nos.^[a](#table-fn2-2473974X20942202){ref-type="table-fn"}^   Assessment of   Data with risk ratios   Quality score         
  ------------------------------------------------------------------------------------------------- ------------------- --------------------------- --------------------------- ---------------------------- --------------------------------------------------------------------- --------------- ----------------------- --------------- ----- ---
  Aouf (2019)^[@bibr18-2473974X20942202]^                                                           No                  Yes                         Yes                         Yes                          Yes                                                                   No              Yes                     No              Yes   6
  Khlifi (2014)^[@bibr22-2473974X20942202],[b](#table-fn6-2473974X20942202){ref-type="table-fn"}^   No                  Yes                         Yes                         Yes                          Yes                                                                   Yes             Yes                     No              Yes   7
  Moumad (2018)^[@bibr24-2473974X20942202]^                                                         No                  Yes                         Yes                         Yes                          Yes                                                                   Yes             Yes                     No              Yes   7
  Makni (2019)^[@bibr23-2473974X20942202]^                                                          No                  Yes                         Yes                         Yes                          Yes                                                                   Yes             No                      No              Yes   6
  Ben Chaaben (2011)^[@bibr20-2473974X20942202]^                                                    No                  Yes                         Yes                         Yes                          Yes                                                                   Yes             Yes                     No              Yes   7
  Ben Nasr (2009)^[@bibr21-2473974X20942202]^                                                       No                  Yes                         Yes                         Yes                          Yes                                                                   No              Yes                     No              Yes   6
  Ben Nasr (2007)^[@bibr19-2473974X20942202]^                                                       No                  Yes                         Yes                         Yes                          Yes                                                                   No              Yes                     No              Yes   6

Abbreviations: HWE, Hardy-Weinberg equilibrium; NCBI, National Center for Biotechnology Information; NPC, nasopharyngeal carcinoma.

NCBI rs numbers can be obtained from the NCBI dbSNP database (available at <https://www.ncbi.nlm.nih.gov/snp/>).

Contained laryngeal carcinomas.

###### 

Gene Polymorphisms and Methodologies of Genetic Studies.

![](10.1177_2473974X20942202-table3)

                                                                               Sample Size                                                                         
  ------------------------------------------------ --------------------------- ------------------------------------------------------------ ----- ---------- ----- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aouf (2019)^[@bibr18-2473974X20942202]^          Tunisia                     259                                                          169   PCR-RFLP   Yes   *NOS3* (T786C,^[c](#table-fn7-2473974X20942202){ref-type="table-fn"},[d](#table-fn8-2473974X20942202){ref-type="table-fn"}^ G894T)
  Khlifi (2014)^[@bibr22-2473974X20942202]^        Tunisia                     145^[e](#table-fn9-2473974X20942202){ref-type="table-fn"}^   261   PCR-RFLP   Yes   *CYP1A1* (--6310C/T^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^), *CYP2D6* (R365H), *NAT1* (A52936T^[c](#table-fn7-2473974X20942202){ref-type="table-fn"}^), *NAT2* (R268K^[c](#table-fn7-2473974X20942202){ref-type="table-fn"}^)
  Moumad (2018)^[@bibr24-2473974X20942202]^        Morocco, Algeria, Tunisia   392                                                          365   PCR-RFLP   Yes   *NQO1* (C609T)
  Makni (2019)^[@bibr23-2473974X20942202]^         Tunisia                     137                                                          263   PCR-RFLP   Yes   *IL-10* (--1082A/G,^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^--819C/T,^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^--592A/C^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^)
  Ben Chaaben (2011)^[@bibr20-2473974X20942202]^   Tunisia                     247                                                          284   PCR        Yes   *IL-12* (+1188A/C^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^)
  Ben Nasr (2009)^[@bibr21-2473974X20942202]^      Tunisia                     180                                                          168   PCR-RFLP   Yes   *COX2* (--765G/C^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^)
  Ben Nasr (2007)^[@bibr19-2473974X20942202]^      Tunisia                     160                                                          169   PCR-RFLP   Yes   *IL-8* (--251 T/A^[f](#table-fn10-2473974X20942202){ref-type="table-fn"}^)

Abbreviations: PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.

Each study type: control.

Positive or negative sign (+ or --): up- or downstream promoter.

Not significant.

Intron variant.

Contained laryngeal carcinomas.

UTR (untranslated region).

As none of the identified genes were similar to the HNSCC candidate genes, a review search was conducted on these identified genes and polymorphs with TCGA-HNSC project data ([**Table 4**](#table4-2473974X20942202){ref-type="table"}, [**Figure 2**](#fig2-2473974X20942202){ref-type="fig"}).

###### 

Gene Polymorphisms From TCGA-HNSC Project Data.

![](10.1177_2473974X20942202-table4)

  Gene^[a](#table-fn12-2473974X20942202){ref-type="table-fn"}^: polymorphism   Amino acid change   Consequence             Type
  ---------------------------------------------------------------------------- ------------------- ----------------------- -----------------
  *NOS3*                                                                                                                   
   R149W                                                                       C\>T                Substitution            Missense
   R262Q                                                                       G\>A                Substitution            Missense
   G440Afs64                                                                   delG                Deletion substitution   Frame shift
   E673K                                                                       G\>A                Substitution            Missense
   A323A                                                                       C\>A                Substitution            Synonymous
  *CYP1A1*                                                                                                                 
   T195_N196ins                                                                insGTC . . .        Insertion               Insertion frame
   V447Afs\*36                                                                 delCCA . . .        Deletion                Frame shift
   S80C                                                                        G\>C                Substitution            Missense
   I401I                                                                       G\>A                Substitution            Synonymous
  *CYP2D6*                                                                                                                 
   L91P                                                                        A\>G                Substitution            Missense
   G471V                                                                       C\>A                Substitution            Missense
   A305V                                                                       G\>A                Substitution            Missense
   Y124C                                                                       T\>C                Substitution            Missense
   L403L                                                                       C\>G                Substitution            Synonymous
  *NAT1*                                                                                                                   
   E147V                                                                       A\>T                Substitution            Missense
   L256V                                                                       C\>G                Substitution            Missense
  *IL12*                                                                                                                   
   Q146E                                                                       G\>C                Substitution            Missense
   Q42H                                                                        C\>A                Substitution            Missense
   T121T                                                                       T\>G                Substitution            Synonymous
   A11A                                                                        T\>C                Substitution            Synonymous
  *COX2*                                                                                                                   
   Y371[\*](#table-fn11-2473974X20942202){ref-type="table-fn"}                 A\>C                Substitution            Stop gained
   V88V                                                                        C\>T                Substitution            Synonymous
   T45T                                                                        G\>A                Substitution            Synonymous
   L1671fs\*10                                                                 InsT                Substitution            Frame shift

Abbreviation: TCGA-HNSC, The Cancer Genome Atlas--Head and Neck Squamous Cell Cancer; \*, stop codon; ins, insertion; del, deletion; fs, frameshift.

*NQO1, NAT2, IL8, IL10*: no data or not enough data.

![*NOS3* showing mutation positions: TCGA-HNSC project database (The Cancer Genome Atlas--Head and Neck Squamous Cell Cancer).](10.1177_2473974X20942202-fig2){#fig2-2473974X20942202}

Discussion {#section10-2473974X20942202}
==========

HNSCC can occur de novo or transform from a premalignant lesion, with the commonest being oral epithelial dysplasias (OEDs)---specifically, oral leukoplakia. Califano et al^[@bibr25-2473974X20942202]^ in 1996 postulated the first genetic multistep characterization of morphologic changes in the oral squamous epithelium that give rise to oral squamous cell carcinoma. They suggested that loss of heterozygosity at chromosomes 3p, 9p, and 17p occurred in OEDs, reflecting early carcinogenesis, while alterations at chromosomes 11q, 4q, and 8q in oral squamous cell carcinoma indicated late-phase carcinogenesis, which may be independent of a previously existent OED. This group's research formed the basis for researchers the world over to demonstrate HNSCC-susceptible genes categorized as candidate and established HNSCC genes.^[@bibr10-2473974X20942202],[@bibr11-2473974X20942202]^

Our study reviewed all the molecular genetic research undertaken in Africa to suggest any variant distinction as compared with other established reports. It was significant to note that all 7 studies were undertaken in North African populations, indicating that sub-Saharan Africa is worst hit by this burden of a lack of research and data when compared with the North African countries. This in itself suggests that any findings might be an inaccurate reflection of the susceptible genes for African HNSCC, as North Africa shares a majority of its ancestry with Eurasia as compared with sub-Saharan Africa.^[@bibr26-2473974X20942202]^ North Africa is surrounded by the Sahara Desert in the south and the Mediterranean Sea in the north and is bounded by Asia and Europe, with the first 2 landmarks acting as prehistoric gene flow barriers and the latter 2 heavily influencing the Maghreb gene pool.^[@bibr27-2473974X20942202]^ More significant, the Sahara Desert acts as a gene flow barrier between the North Africa and sub-Saharan Africa.

This review reported the interrogation of several gene target variants by using a polymerase chain reaction--based molecular technique---restriction fragment length polymorphism---which locates a DNA template within a sequence. Considering the low strength of this technique, it is possible that some mutations were missed since restriction fragment length polymorphism is known to be of limited utility, with a base change sensitivity \<80%.^[@bibr28-2473974X20942202]^ While some of the techniques used may have been contemporary for their time, high throughput--based study may be necessary to interrogate for variants in the entire genome.

Surprisingly, none of the known HNSCC candidate genes were interrogated in these African studies, and significantly, the justification for interrogating some of these genes and polymorphisms showed very little correlation to the TCGA-HNSC project database. While some of these identified genes (*NOS3, CYP1A1, CYP2D6, NAT1, NAT2, NQO1, IL8, IL10, IL12, COX2*) are susceptible to carcinogenesis, their review search with the TCGA-HNSC project database revealed no HNSCC correlation. Perhaps a larger-scale study from multiple head and neck cancer sites and the use of high-throughput methods for variant screening may have provided more genetic data.

In addition, no study in this review undertook replication and validation assays for its genetic polymorphisms. This made it difficult to demonstrate any genetic correlation of these polymorphs to African-based populations HNSCC, thus rendering the resolution to mainly suggestive rather than statistically significant. In addition, the majority of these studies did not report a power calculation or a genotyping error, and this may have resulted in these studies being underpowered with an increased genotyping error. Furthermore, the underpowered nature of the study would not support the statistically significant association of the polymorphisms reported. An effective sample size for a threshold **≥**80% statistical power is essential, by using an appropriate web browser program with a suggested average disease prevalence, an allele frequency of 0.25, an allele odds ratio of 1.0, and a case-control ratio of 1:1.^[@bibr29-2473974X20942202],[@bibr30-2473974X20942202]^

Several candidate genes (*TP53, CDKN2A, NOTCH1, PIK3CA, FAT1, HRAS, CASP8, PTEN*) and their functional genetic polymorphisms have been identified as playing a role in HNSCC causation.^[@bibr10-2473974X20942202],[@bibr16-2473974X20942202]^ According to the present study, none of these known candidate genes have been researched in Africa, highlighting a research gap in the molecular etiology of African population HNSCC.

In conclusion, studies on HNSCC candidate genes needs to be undertaken in Africa, with more of these studies in sub-Saharan Africa. Importantly, these studies should be large scale with multiple head and neck cancer sites and should employ high-throughput methods for improved causal mapping.

Members of the head and neck oncology research group, Medical Research Centre, Lagos State University College of Medicine.

**Author Contributions:** **Eyituoyo Okoturo**, contributed to conception, design, data acquisition and interpretation, performed all statistical analyses, drafted and critically revised the manuscript, accountable for all aspects; **Anslem Osasuyi**, contributed to conception, design, data acquisition and analysis, and critically revised the manuscript and accountable for all aspects; **Taofiq Opaleye**, contributed to design, data analysis, and critically revised the manuscript and accountable for all aspects.

**Disclosures:** **Competing interests:** None.

**Sponsorships:** None.

**Funding source:** None.
